Enerzair
-
Valeo Pharma Impresses Again with 210% Quarterly Year-over-Year Revenue Growth
Valeo Pharma Inc. (TSX: VPH | OTCQB: VPHIF) (“Valeo”) just released their FQ1/2023 earnings results and impressed again.…
-
Steve Saviuk on how Valeo Pharma’s ‘life changing’ products have delivered the strong growth forecasted for 2022
In this InvestorIntel interview, Tracy Weslosky interviews Valeo Pharma Inc.’s (TSX: VPH | OTCQB: VPHIF) Founder, CEO and…
-
Valeo Pharma keeps delivering with a 100% revenue growth forecast in 2022 and more new effective pharmaceuticals
Early in 2022 InvestorIntel updated readers about a company that was growing its revenue at an incredible rate…
-
Valeo Pharma revenues jump on increased market share from growing drug portfolio
Valeo Pharma Inc. (TSX: VPH | OTCQB: VPHIF) is a Canadian pharmaceutical company that is seeing significant success…
-
Steve Saviuk on Valeo Pharma’s TSX Listing and Q1-22 revenues of $4.2 million, up 128% over Q1-21
In a recent InvestorIntel interview, Tracy Weslosky interviews Valeo Pharma Inc.’s (TSX: VPH | OTCQB: VPHIF) Founder, CEO…
-
Valeo Pharma’s rocketing growth in sales points to positive cash flow this year
Stock market investors love companies that can quickly expand and rapidly grow their revenues. The very best of…
